With regard to Health Canada and the Pfizer/BioNtech Phase 3 vaccine clinical trial that was used for a population-wide approval of novel medical intervention: (a) what are, in percentages, the benefits conferred by vaccination versus control (placebo) considering all-cause morbidity (level 1 evidence of benefit or harm) in the said trial in terms of (i) adverse events, (ii) severe adverse events, (iii) serious adverse events, (iv) deaths; (b) what is, in terms of percentage, the amount that the vaccine reduced the transmission of COVID-19 in the vaccine arm compared to the placebo arm in the said trial; (c) what were the bio-markers for which trial participants were systematically tested at the commencement, during, and at the conclusion of the trial to test for the safety of the product evaluated in the said trial; and (d) what were, in terms of percentage, the absolute risk reduction provided by the vaccine?
In the House of Commons on March 21st, 2022. See this statement in context.